Corticosteroids to Treat Pancreatitis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone

In brief

This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.

Key facts

Study ID

NCT05160506

Run by

Beth Israel Deaconess Medical Center

People needed

86

Starts

2022-03-06

Expected to finish

2027-04-01

Last updated by the study team

2026-02-18

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult (≥18 years)
• Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.
• Admission or planned admission to an intensive care unit
• SOFA disease severity score ≥3 (or at least 3 points above a known baseline)

You may not qualify if…

• Known diagnosis of autoimmune pancreatitis
• Existing clinical indication for corticosteroids at a dose >5mg of oral prednisone daily (or equivalent)
• Contraindication to receiving corticosteroids
• Protected populations (prisoners)
• Pregnancy

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.